期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

狼疮性肾炎的生物靶向治疗 被引量：5

Biological targeted therapy for lupus nephritis
原文传递
导出
摘要 狼疮性肾炎(LN)的治疗药物主要为糖皮质激素及免疫抑制药,但其存在不同程度的不良反应,且部分患者无效或反复复发。生物制剂为LN的治疗提供了新的选择,本文对此进行综述。 The treatment of lupus nephritis mainly depends on glucocorticoid and immunosupressants,but these drugs all have some extent of side effects.Furthermore,some patients may resistant to the drugs mentioned above,and renal flare is nor uncommon in SLE,which are difficult problems bothering physicians in rheumatology and nephrology.Biological agents are new therapies for lupus nephritis which have shown their effect and safety.Our aim was to review the treatment of lupus nephritis with these drugs.
作者 石永兵 冯胜
机构地区 苏州大学附属第二医院肾内科
出处 《临床药物治疗杂志》 2012年第4期18-21,共4页 Clinical Medication Journal
关键词 狼疮性肾炎 利妥昔单抗 贝利单抗
分类号 R593 [医药卫生—内科学] R979.5 [医药卫生—药品]
  • 相关文献

参考文献12

  • 1Bernatsky S, Boivin JF, Joseph L,et al. Mortality in systemic lupus erythematosus [ J ] . Arthritis Rheum,2006,54:2550-2557.
  • 2Lu TY, Ng KP, Cambridge G,et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients [ J ] . Arthritis Rheum,2009,61:482-487.
  • 3Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 158 cases [ J ] . Lupus,2009,18:767-776.
  • 4Dorner T, Kaufmann J, Wegener WA,et al. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus [ J ] . Arthritis Res Ther,2006,8:R74.
  • 5Petri M, Hobbs K, Gordon C, et al. Randomized controlled trials(RCTS) of epratuzumab (anti-CD22 mAb targeting B-cells) reveal clinically meaningful improvements in patients (pts) with moderate/severe SLE flares [ OP-0016 ] [ J ] . Ann Rheum Dis, 2008,67:$53.
  • 6Navarra SV, Guzm6n RM, Gallacher AE,et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial [ J ] . Lancet, 2011,377:721- 731.
  • 7Furie R, Petri M, Zamani O, et al. A phase Ⅲ, randomized, placebo- controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus [ J ] Arthritis Rheum,2011,63:3918-3930.
  • 8Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis [ J ] . Nat Rev Rheumatol,2009,5:348-351.
  • 9Mosca M, Baldini C, Bombardieri S. LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus [ J ] . Expert Opin Pharmacother, 2007,8:873-879.
  • 10Study of LJP 394 in lupus patients with history of renal disease (ASPEN) [ R/OL ] . March 30, 2009. Available at http://www.clinicaltrials.gov Accessed December 29, 2010.

同被引文献96

引证文献5

二级引证文献77

临床药物治疗杂志
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部